Corrias M V, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa A R, Dau D, Scuderi F, Carlini B, Bianchi M, Casale F, Faulkner L, Garaventa A
Department of Experimental and Laboratory Medicine, Laboratory of Oncology, Gaslini Institute, Largo Gaslini, 5, Genoa 16147, Italy.
Br J Cancer. 2008 Jan 29;98(2):263-9. doi: 10.1038/sj.bjc.6604179. Epub 2008 Jan 8.
The impact of bone marrow (BM) GD2-positive cells on survival has been evaluated in 145 Italian children with localised neuroblastoma (NB) evaluated at diagnosis by anti-GD2 immunocytochemistry. Nineteen of these (13.1%) were found to be BM GD2-positive, with the number of positive cells ranging between 1 and 155 out of 1 x 10(6) total cells analysed. Seven/19 (38.8%) GD2-positive vs 12/126 (9.5%) GD2-negative patients relapsed. The 5-year event-free survival (EFS) and overall survival of the GD2-positive patients was significantly worse than that of the GD2-negative ones (62.2 vs 89.9%, P<0.001; and 74.9 vs 95.9%, P=0.005, respectively). GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion. Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children positive for either one of these two markers (EFS=96.9 vs 66.0%, P<0.001). In conclusion, GD2 positivity may represent a prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations might help identifying patients that require a more careful follow-up.
通过抗GD2免疫细胞化学方法，对145例意大利局部神经母细胞瘤（NB）患儿进行诊断评估，以研究骨髓（BM）GD2阳性细胞对生存的影响。其中19例（13.1%）被发现骨髓GD2呈阳性，在所分析的1×10⁶个总细胞中，阳性细胞数量在1至155个之间。GD2阳性患者中有7/19（38.8%）复发，而GD2阴性患者中有12/126（9.5%）复发。GD2阳性患者的5年无事件生存率（EFS）和总生存率显著低于GD2阴性患者（分别为62.2%对89.9%，P<0.001；74.9%对95.9%，P=0.005）。GD2阳性与其他已知风险因素无关，尤其是与Myc-N扩增和1p缺失无关。在Myc-N阴性患者中，GD2和1p缺失均为阴性的患者的EFS显著优于这两种标志物中任一项为阳性的儿童（EFS=96.9%对66.0%，P<0.001）。总之，GD2阳性可能是无Myc-N扩增的非转移性NB患者的预后标志物，其与基因改变相结合可能有助于识别需要更密切随访的患者。
Zotero 插件